Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Decrease in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 2,680,000 shares, a drop of 14.9% from the November 30th total of 3,150,000 shares. Currently, 5.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 329,100 shares, the short-interest ratio is currently 8.1 days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,112 shares during the period. PDT Partners LLC bought a new position in Astria Therapeutics in the 3rd quarter valued at about $140,000. SG Americas Securities LLC acquired a new position in Astria Therapeutics during the 3rd quarter valued at about $155,000. Hsbc Holdings PLC bought a new stake in Astria Therapeutics during the 2nd quarter worth approximately $171,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Astria Therapeutics in the third quarter worth approximately $228,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Stock Down 2.9 %

ATXS traded down $0.27 during midday trading on Friday, hitting $9.15. The company had a trading volume of 244,427 shares, compared to its average volume of 586,688. The company has a market capitalization of $516.37 million, a price-to-earnings ratio of -4.38 and a beta of 0.67. The stock's 50 day moving average price is $10.45 and its 200 day moving average price is $10.72. Astria Therapeutics has a 52 week low of $6.58 and a 52 week high of $16.90.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ATXS. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Astria Therapeutics has a consensus rating of "Buy" and an average price target of $25.60.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.